Entresto

ESC: Novartis looks for the bright side in flopped Entresto heart failure study
ESC: Novartis looks for the bright side in flopped Entresto heart failure study
Fierce Pharma
Novartis
heart failure
Entresto
clinical trials
ESC
European Society of Cardiology
Flag link:
5 Reasons Novartis Shareholders Aren't Shaken
5 Reasons Novartis Shareholders Aren't Shaken
Yahoo/Motley Fool
Novartis
Zolgensma
FDA
shareholders
Entresto
Flag link:
Novartis heart drug fails trial, curbing growth prospects
Novartis heart drug fails trial, curbing growth prospects
Yahoo/Reuters
Novartis
heart failure
Entresto
clinical trials
Flag link:
American College of Cardiology Conference Roundup - day 1
American College of Cardiology Conference Roundup - day 1
CP Wire
American College of Cardiology
Novartis
Entresto
heart failure
Edwards Lifesciences
Apple
TAVR
wearables
clinical trials
Apple Watch
atrial fibrillation
Flag link:
American College of Cardiology Conference Roundup - day 1
American College of Cardiology
Novartis
Entresto
heart failure
Edwards Lifesciences
Apple
TAVR
wearables
clinical trials
Apple Watch
atrial fibrillation
Flag link:
Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study
Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study
Endpoints
Novartis
Entresto
Flag link:
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
NASDAQ.com
Novartis
earnings
Cosentyx
Entresto
Flag link:
One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology
One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology
Fierce Pharma
Novartis
Entresto
drug launches
heart failure
oncology
Flag link:
After a slow start, Novartis finally gains market traction with heart drug Entresto
After a slow start, Novartis finally gains market traction with heart drug Entresto
Fierce Biotech
Novartis
Entresto
heart failure
Flag link:
Drugmakers face challenges marketing new heart drugs
Drugmakers face challenges marketing new heart drugs
Medical Marketing and Media
drug marketing
Amgen
Repatha
Novartis
Entresto
Ilaris
canakinumab
Merck
Anacetrapib
Flag link:
Novartis set to ride Entresto wave, says report
Novartis set to ride Entresto wave, says report
BioPharma Dive
Novartis
Entresto
Flag link:
How Novartis Is Aiming to Increase Entresto Sales in 2017
How Novartis Is Aiming to Increase Entresto Sales in 2017
Market Realist
Novartis
Entresto
heart failure
Flag link:
What Could Boost Medicare Demand for Novartis’s Entresto?
What Could Boost Medicare Demand for Novartis’s Entresto?
Market Realist
Novartis
Entresto
Medicare
heart failure
Flag link:
Novartis Heart Failure Drug Beats Enalapril
Novartis Heart Failure Drug Beats Enalapril
Investopedia
Novartis
heart failure
Entresto
Enalapril
Flag link:
Novartis heart-failure med Entresto cuts A1c, insulin starts in diabetics: analysis
Novartis heart-failure med Entresto cuts A1c, insulin starts in diabetics: analysis
Fierce Pharma
Entresto
Novartis
diabetes
insulin
Flag link:
Novartis continues data push for Entresto
Novartis continues data push for Entresto
BioPharma Dive
Novartis
Entresto
heart failure
Flag link:
Novartis Needs to Stem the Bleeding From Gleevec Decline
Novartis Needs to Stem the Bleeding From Gleevec Decline
Yahoo/GuruFocus
Novartis
Gleevec
Entresto
Flag link:
Can Novartis Win the Entresto Bet?
Can Novartis Win the Entresto Bet?
Yahoo/GuruFocus
Novartis
Entresto
Flag link:
Novartis warns profits may slip as it bets an extra $200M on Entresto
Novartis warns profits may slip as it bets an extra $200M on Entresto
Fierce Pharma
Novartis
Entresto
Flag link:
How to save 28,000 heart patients a year? Use Novartis' Entresto, JAMA says
How to save 28,000 heart patients a year? Use Novartis' Entresto, JAMA says
Fierce Pharma
JAMA
Novartis
Entresto
heart failure
Flag link:

Pages